CHEMICALS AND DRUGS Chemical Actions and Uses [D27] Chemical Actions and Uses Pharmacologic Actions [D27.505] Pharmacologic Actions Molecular Mechanisms of Pharmacological Action [D27.505.519] Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors [D27.505.519.389] Enzyme Inhibitors 5-Lipoxygenase-Activating Protein Inhibitors [D27.505.519.389.086] 5-Lipoxygenase-Activating Protein Inhibitors Acetaldehyde Dehydrogenase Inhibitors [D27.505.519.389.089] Acetaldehyde Dehydrogenase Inhibitors Adenosine Deaminase Inhibitors [D27.505.519.389.092] Adenosine Deaminase Inhibitors Adenylyl Cyclase Inhibitors [D27.505.519.389.108] Adenylyl Cyclase Inhibitors Aromatic Amino Acid Decarboxylase Inhibitors [D27.505.519.389.124] Aromatic Amino Acid Decarboxylase Inhibitors Calcineurin Inhibitors [D27.505.519.389.174] Calcineurin Inhibitors Carbonic Anhydrase Inhibitors [D27.505.519.389.200] Carbonic Anhydrase Inhibitors Catechol O-Methyltransferase Inhibitors [D27.505.519.389.237] Catechol O-Methyltransferase Inhibitors Cholinesterase Inhibitors [D27.505.519.389.275] Cholinesterase Inhibitors Cyclooxygenase Inhibitors [D27.505.519.389.310] Cyclooxygenase Inhibitors Gamma Secretase Inhibitors and Modulators [D27.505.519.389.315] Gamma Secretase Inhibitors and Modulators Glycoside Hydrolase Inhibitors [D27.505.519.389.320] Glycoside Hydrolase Inhibitors Cytochrome P-450 Enzyme Inhibitors [D27.505.519.389.335] Cytochrome P-450 Enzyme Inhibitors Folic Acid Antagonists [D27.505.519.389.350] Folic Acid Antagonists Histone Deacetylase Inhibitors [D27.505.519.389.360] Histone Deacetylase Inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.389.370] Hydroxymethylglutaryl-CoA Reductase Inhibitors Integrase Inhibitors [D27.505.519.389.375] Integrase Inhibitors beta-Lactamase Inhibitors [D27.505.519.389.400] beta-Lactamase Inhibitors Lipoxygenase Inhibitors [D27.505.519.389.480] Lipoxygenase Inhibitors Monoamine Oxidase Inhibitors [D27.505.519.389.616] Monoamine Oxidase Inhibitors Nucleic Acid Synthesis Inhibitors [D27.505.519.389.675] Nucleic Acid Synthesis Inhibitors Ornithine Decarboxylase Inhibitors [D27.505.519.389.705] Ornithine Decarboxylase Inhibitors Phosphodiesterase Inhibitors [D27.505.519.389.735] Phosphodiesterase Inhibitors Phosphoinositide-3 Kinase Inhibitors [D27.505.519.389.736] Phosphoinositide-3 Kinase Inhibitors Phospholipase A2 Inhibitors [D27.505.519.389.737] Phospholipase A2 Inhibitors Poly(ADP-ribose) Polymerase Inhibitors [D27.505.519.389.739] Poly(ADP-ribose) Polymerase Inhibitors Prolyl-Hydroxylase Inhibitors [D27.505.519.389.740] Prolyl-Hydroxylase Inhibitors Protease Inhibitors [D27.505.519.389.745] Protease Inhibitors Protein Kinase Inhibitors [D27.505.519.389.755] Protein Kinase Inhibitors Protein Synthesis Inhibitors [D27.505.519.389.760] Protein Synthesis Inhibitors Proton Pump Inhibitors [D27.505.519.389.848] Proton Pump Inhibitors Steroid Synthesis Inhibitors [D27.505.519.389.870] Steroid Synthesis Inhibitors Topoisomerase Inhibitors [D27.505.519.389.892] Topoisomerase Inhibitors Uncoupling Agents [D27.505.519.389.936] Uncoupling Agents

Folic Acid Antagonists - Preferred

Concept UI	M0008662
Scope note	Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033)
Preferred term	Folic Acid Antagonists
Entry term(s)	Acid Antagonists, Folic Antagonists, Folic Acid Antifolate Antifolates Dihydrofolate Reductase Inhibitor Dihydrofolate Reductase Inhibitors Folic Acid Antagonist Inhibitors, Dihydrofolate Reductase Reductase Inhibitors, Dihydrofolate

Folic Acid Metabolism Inhibitors - Broader

Concept UI	M0587610
Preferred term	Folic Acid Metabolism Inhibitors